How many investments has Prospect Venture Partners made?

Prospect Venture Partners has 34 tracked investments, 11 of which have exited.

What stage does Prospect Venture Partners invest at?

Prospect Venture Partners invests at the Seed, Series A, Growth, Late Stage stages.

What is Prospect Venture Partners's typical check size?

Prospect Venture Partners typically writes checks of $3M – $5M.

What sectors does Prospect Venture Partners focus on?

Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.

Where is Prospect Venture Partners located?

Prospect Venture Partners is headquartered in Menlo Park, US.

Does Prospect Venture Partners lead rounds?

Yes, Prospect Venture Partners leads investment rounds.

Who does Prospect Venture Partners co-invest with?

Prospect Venture Partners most often shares deals with New Enterprise Associates (NEA), Venrock, Foresite Capital, among 39 tracked co-investors.

Prospect Venture Partners

Venture capital

Menlo Park · Seed–Late Stage · 3 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Prospect Venture Partners

20 people in our graph can introduce you to the Prospect Venture Partners team.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Prospect Venture Partners team. We find them
2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict

Investment thesis

Prospect Venture Partners focuses on biomedical innovation, supporting entrepreneurs pursuing growth opportunities across health care, biotechnology, and medical devices. The firm partners closely with management teams to help build strong companies, drawing on a track record established since its founding in 1997.

Invests inBiotech Deep Tech Digital Health Healthtech Medical Devices Menlo Park Palo Alto United States

Source: firm website, verified Aug 3, 2026.

Leave your own feedback

Stage

Seed–Late Stage

Check

$3M – $5M

Menlo Park, California, US

Leads rounds

Leads

Instruments

Equity

Founded

1997

AUM

$100M

Tracked investments

IPOs

Acquisitions

Team · 3 people

from the firm's website & public directories

Alexander E. Barkas· Co-Founder

Alex Barkas was a co-founder of Prospect Ventures, which he established to focus on developing and commercializing biomedical technologies. He previously served as a Partner at Kleiner Perkins Caufield & Byers, where he worked on biotechnology and medical device investing and co-founded and led several biotechnology companies, and earlier founded the healthcare consulting firm BioBridge Associates. He held a PhD in Biology from New York University and a BA in Biology from Brandeis University, with prior research experience at Memorial Sloan Kettering Cancer Center, the Toronto Hospital for Sick Children, the Whitehead Institute at MIT, and Duke University.

David Schnell· Managing Director· Menlo Park, California

David Schnell is a Managing Director who co-founded Prospect Ventures in 1997, a firm focused on biomedical companies. He was previously a Partner at Kleiner Perkins Caufield & Byers, where he invested in early-stage biotechnology companies, and co-founded and served as CEO of Healtheon Corporation, which later merged with WebMD. Earlier he spent seven years at Sandoz Pharmaceuticals (now Novartis) in executive roles; he holds an MD from Harvard Medical School and an MA and BS from Stanford.

dschnell@prospectventures.com

Russell Hirsch· Managing Director

Russell Hirsch is a co-founder and Managing Director of Prospect Venture Partners, focusing on life science investments in biotechnology and medical device companies. He previously served as a General Partner at the Mayfield Fund, where he helped build its biotechnology and medical device practice. Before his venture career, he worked as a research scientist, earning his MD and PhD from UCSF and conducting research on hepatitis B viral replication.

russell@prospectventures.com

Founder mafia

2 people who came through Prospect Venture Partners went on to found or lead other companies.

Scott WolfPartnerFounded Cardiac Dimensions +3 Stella SarrafScientific AdvisorFounded Spinogenix +1

What they invest in

from 19 of 34 portfolio companies

Healthtech ×13Biotech ×12Medical Devices ×6Digital Health ×3Enterprise Software ×2Hardware ×2New Materials ×2Advanced Manufacturing ×1

HQs:United States×15Switzerland×1United Kingdom×1

Investments · 34 tracked

founders shown can be your intro path

By year:2016 · 1 2015 · 2 2012 · 2 2011 · 16 dated

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)in S. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBessemer Venture Partners F-Prime Capital Foresite Capital Hercules Capital, Inc.OrbiMed Ridgeback Capital +1 more

Curileumcurileum.com in✓ verified

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.

BiotechHealthtechMedical DevicesLondon, GB

Dr Jeff Moore(Founder & CEO)

Co-investorsAtlas Venture Biotechnology Value Fund Canaan Partners Oxford Technology Management

20n20n.comSeedDefunct

20n uses machine learning and computational biology to predict DNA sequences for industrial biotech and pharmaceutical applications.

AI & Machine LearningBiotechHealthtechSan Francisco, US

Saurabh Srivastava(Founder)inChris Anderson(Founder)

Co-investorsY Combinator Blumberg Capital Great Oaks Venture Capital Khosla Ventures Lin, Bill | A10 Ventures Point Reyes Management +2 more

Amicus Therapeuticsamicusrx.com in

Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.

BiotechHealthtechCranbury, US

Daphne Quimi(Executive Officer)John Crowley(Founder)William D. Baird, III(Executive Officer)

BoardCraig A. Wheeler(Director)Ted W. Love(Director)inMargaret G. McGlynn(Director)

Co-investorsAvoro Capital Advisors Canaan Partners Frazier Life Sciences New Enterprise Associates (NEA)

Gloucester Pharmaceuticalsbms.com in 𝕏Acquired

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsKleiner Perkins New Enterprise Associates (NEA)Nextech Invest Rho Capital Partners Rho Ventures RiverVest Venture Partners +2 more

GrubMarketgrubmarket.com in 𝕏

GrubMarket is a food tech company operating a B2B and B2C marketplace in the U.S. and Canada, offering both wholesale produce delivery at discounted prices and AI-powered SaaS software solutions for food supply chain businesses including inventory management, warehouse operations, and eCommerce platforms.

B2B MarketplacesE-commerceEnterprise SoftwareFoodTechLogistics & Supply ChainSaaSSan Francisco, US

Mike Xu(Founder)in

Board Hans Tung(Director)in

Co-investorsAlumni Ventures Bascom Ventures Battery Ventures Builders + Backers Castor Ventures Celtic House Asia Partners +50 more

Jazz Pharmaceuticaljazzpharma.com in 𝕏

Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.

BiotechHealthtech

Co-investorsLongitude Capital Rex Health Ventures Solas BioVentures

Kythera Biopharmaceuticalsallergan.comSep 2011Acquired

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Allen Chao(Founder)

Co-investorsAisling Capital ARCH Venture Partners MESA VERDE VENTURE PARTNERS Schooner Capital ALTITUDE LIFE SCIENCE VENTURES Foley Ventures +2 more

Lullylullysleep.com inDefunct

Lully develops an under-mattress device that uses timed vibrations to prevent night terrors in children.

HealthtechWellness & FitnessSan Francisco, US

Varun Boriah(Founder)in Andy Rink(Founder)in

Co-investorsStartX Y Combinator 8capita Agrolimen Ventures Astia GFO Companies +3 more

Nanosysnanosys.com inAcquired

Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.

Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US

Jason Hartlove(Executive Officer, Director)inJian Chen(Executive Officer)in Russell Kempt(Executive Officer)inNoland Granberry(Executive Officer)inDr. Martin Devenney(Co Chief Executive Officer and Assistant Secretary)Dr. Hirokazu Sasaki(President & CEO and Treasurer, Shoei Electronic Materials, Inc. • Operating Officer & Division Manager QD Business Dept., Shoei Chemical, Inc.)

Co-investorsArcher Capital Group Archer Venture Capital Structural Capital TEL Venture Capital, Inc.Venrock ARCH Venture Partners +4 more

NinePoint Medical in

HealthtechBedford, US

Christopher von Jako(Executive Officer, Director)inJudith M. Huber(Executive Officer)inCharles Carignan(Executive Officer, Director)Eric Swanson(Director)

Board Russell Hirsch(Director)Mark Levin(Director)in

Co-investorsThird Rock Ventures

Opus Medicalopusmedical.com in

Opus Medical provides personalized case management services for injured workers, matching clinical oversight to the severity of each injury.

Digital HealthEnterprise SoftwareHealthtechInsurTechMedical DevicesNashville, US

Melissa D. Tonn(Chief Medical Officer)in

Co-investorsCouncil

Portola Pharmaceuticalsportola.com 𝕏acquired by Alexion

Portola develops research and investigates new targets, modalities, and technologies to address rare disease challenges for patients and their families.

BiotechDigital HealthHealthtechMedical Devices

Partner Russell Hirsch· led

Co-investorsBluebird Ventures Frazier Life Sciences Lightstone Ventures Khosla Ventures NFDG

Senomyxfirmenich.com in 𝕏Acquired

Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.

ConsumerHealthtechNew MaterialsGeneva, CH

Gilbert Ghostine in

Co-investorsBay City Capital Rho Ventures

SentreHeartsentreheart.com 𝕏Sep 2016

SentreHeart appears to now redirect to AtriCure, Inc., a medical device company.

BiotechHardwareHealthtechMedical DevicesRedwood City, US

Russell Seiber(Executive Officer, Director)in Pam Simons(Executive Officer)inGreg Fung(Executive Officer)Robert Strasser(Executive Officer)in

Board Phil Young(Director)inVictor Tong(Director)

Partner Russell Hirsch· led

Co-investorsDecheng Capital US Venture Partners Deerfield Management Company U.S. Venture Partners Vivo Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Amira PharmaceuticalsAveo PharmaceuticalsAzelon PharmaceuticalsCabochonComplete GenomicsHansen MedicalHealth Systems TechnologiesIdun PharmaceuticalsInfinity PharmaceuticalsMillennium PharmaceuticalsNgm BiopharmaceuticalsNovaceptRinat NeuroscienceSatori PharmaceuticalsSurgRxTercicaTherOxTopica PharmaceuticalsTrubion

Exits · 11

1 IPOs · 10 acquisitions · showing 7

InsmedNASDAQ: INSMAmira Pharmaceuticalsacq. by Bristol Myers SquibbMillennium Pharmaceuticalsacq. by Takeda PharmaceuticalNgm Biopharmaceuticalsacq. by The Column GroupPortola Pharmaceuticalsacq. by AlexionTopica Pharmaceuticalsacq. by MedicisTrubionacq. by Emergent Biosolutions

Frequently asked questions

How many investments has Prospect Venture Partners made?: Prospect Venture Partners has 34 tracked investments, 11 of which have exited.
What stage does Prospect Venture Partners invest at?: Prospect Venture Partners invests at the Seed, Series A, Growth, Late Stage stages.
What is Prospect Venture Partners's typical check size?: Prospect Venture Partners typically writes checks of $3M – $5M.
What sectors does Prospect Venture Partners focus on?: Prospect Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is Prospect Venture Partners located?: Prospect Venture Partners is headquartered in Menlo Park, US.
Does Prospect Venture Partners lead rounds?: Yes, Prospect Venture Partners leads investment rounds.
Who does Prospect Venture Partners co-invest with?: Prospect Venture Partners most often shares deals with New Enterprise Associates (NEA), Venrock, Foresite Capital, among 39 tracked co-investors.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Panacea Venture

Panacea Venture is a global investment firm, spun out from Kleiner Perkins, focused on life sciences and healthcare innovation. It invests across geographies and stages, from company formation through expansion and public markets.